← Eichor
Condition: Osteosarcoma Recurrent Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Osteosarcoma Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Phase 1 · 1 location(s) · Emory University · NCT06492954Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07479732A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 · 6 location(s) · Nationwide Children's Hospital · NCT05135975Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Phase 1 · 3 location(s) · Peking University People's Hospital · NCT06340204Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiot
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06114225B7-H3 NIR Imaging for Osteosarcoma Surgery
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06778603NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neurob
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT07211737Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Phase 1 · 1 location(s) · Emory University · NCT07144254Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcom
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT05019703Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplast
Phase 1/Phase 2 · 28 location(s) · National Cancer Institute (NCI) · NCT04616560DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Montefiore Medical Center · NCT06892678Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07227571Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Phase 1 · 8 location(s) · Amgen · NCT07297979Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/
Phase 1 · 1 location(s) · Emory University · NCT05400603Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive O
Phase 1/Phase 2 · 3 location(s) · MedPacto, Inc. · NCT05588648Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatme
Phase N/A · 79 location(s) · Children's Oncology Group · NCT01790152Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sa
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06827717HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT04995003Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Phase 1 · 4 location(s) · Children's Hospital of Philadelphia · NCT06156410Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Phase 2 · 2 location(s) · Hackensack Meridian Health · NCT05726383
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.